http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007031100-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0133bc3173f16e36a9fc4ba2f7ac8d4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c6276f885eca58fe53e48edeed6a498
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
filingDate 2005-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10eea3ebfb1bb97be64e72c61997fee9
publicationDate 2007-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2007031100-A1
titleOfInvention Active immunotherapy of life-threatening systemic inflammation
abstract This invention describes the use of HMGB1 or immunogenic fragments thereof for the active immunoprophylaxis and treatment of systemic inflammatory conditions, such as sepsis, endotoxic shock, hemorrhagic shock and other related syndromes. The administration of HMGB1 or of peptides derived therefrom induces an immune response which is characterized by the generation of anti-HMGB1 antibodies capable of neutralizing the activity of the circulating HMGB1 by inhibiting its ability to promote the secretion of the pro-inflammatory cytokine TNF-α. The efficacy of the prophylactic treatment can be measured by a method which measures the neutralizing activity of the antibodies against the biological effect of HMGB1 on human monocytes.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10550165-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9919010-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9688733-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009202500-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9623078-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11298403-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11197895-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11191786-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10364276-B2
priorityDate 2005-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004004763-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005026209-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0047104-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004061456-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004046345-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02074337-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005025604-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402238
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57199466
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819

Total number of triples: 34.